Content about Endocrine system

May 24, 2011
American Diabetes Association announces new research grant for diabetes technology

The American Diabetes Association announced that it will fund research that will examine the effectiveness of technology-based diabetes management devices.

ALEXANDRIA, Va. — The American Diabetes Association announced that it will fund research that will examine the effectiveness of technology-based diabetes management devices.

The studies, funded by the American Diabetes Association/Medtronic Technology in Diabetes Fellowship, will utilize Medtronic's CareLink database — a database of anonymous continuous glucose monitoring and insulin pump-derived data — to assess, evaluate and correlate the application of this and similar technologies used by patients with insulin-treated diabetes.

May 23, 2011
New ovulation test tracks LH levels

Church & Dwight in April launched the First Response Digital Ovulation Test, a new at-home ovulation test that can detect a woman’s personal luteinizing hormone surge — the hormonal indication of ovulation — based on her own individual hormone levels.

PRINCETON, N.J. — Church & Dwight in April launched the First Response Digital Ovulation Test, a new at-home ovulation test that can detect a woman’s personal luteinizing hormone surge — the hormonal indication of ovulation — based on her own individual hormone levels.

May 13, 2011
Study finds link between insomnia, high insulin resistance among diabetics

Diabetics that have trouble sleeping likely experience high insulin resistance and have a more difficult time controlling the disease, according to study findings published in the June issue of Diabetes Care.

NEW YORK — Diabetics that have trouble sleeping likely experience high insulin resistance and have a more difficult time controlling the disease, according to study findings published in the June issue of Diabetes Care.

Researchers said they monitored the sleep of 40 subjects with diabetes for a duration of six nights and also measured the subjects' insulin and glucose levels during clinical examinations. The subjects also reported if they generally suffered from symptoms of such sleep disturbances as insomnia, snoring or sleep apnea.

May 2, 2011
FDA approves Abbott's AndroGel

The Food and Drug Administration has approved a treatment made by Abbott for low testosterone in men, the drug maker said Friday.

ABBOTT PARK, Ill. — The Food and Drug Administration has approved a treatment made by Abbott for low testosterone in men, the drug maker said Friday.

Abbott announced the approval of AndroGel (testosterone gel) in the 1.62% strength, a clear, odorless topical gel for men with hypogonadism. The company already markets AndroGel in the 1% strength.

The new gel contains 40.5 mg of testosterone in two pump presses, while AndroGel 1% contains 50 mg in four pump presses, but the company said the two were not interchangeable.

April 29, 2011
Medical costs for youth with diabetes more than $9,000 a year

According to a study by the Centers for Disease Control and Prevention released Wednesday, young people with diabetes face substantially higher medical costs than children and teens without the disease. The study found annual medical expenses for youth with diabetes were $9,061, compared with $1,468 for youth without the disease.

ATLANTA — According to a study by the Centers for Disease Control and Prevention released Wednesday, young people with diabetes face substantially higher medical costs than children and teens without the disease. The study found annual medical expenses for youth with diabetes were $9,061, compared with $1,468 for youth without the disease.

April 27, 2011
Columbia Labs, Watson submit NDA for Prochieve

A drug designed to reduce the risk of premature birth among pregnant women has been submitted to the Food and Drug Administration for approval.

LIVINGSTON and PARSIPPANY, N.J. — A drug designed to reduce the risk of premature birth among pregnant women has been submitted to the Food and Drug Administration for approval.

April 27, 2011
First Response introduces at-home ovulation test

Church & Dwight on Tuesday announced the launch of its First Response digital ovulation test, a new at-home ovulation test that can detect a woman's personal luteinizing hormone, or LH, surge — the hormonal indication of ovulation — based on her own individual hormone levels.

PRINCETON, N.J. — Church & Dwight on Tuesday announced the launch of its First Response digital ovulation test, a new at-home ovulation test that can detect a woman's personal luteinizing hormone, or LH, surge — the hormonal indication of ovulation — based on her own individual hormone levels.

April 26, 2011
Watson joins Walgreens on New Life Agency's Fertility Pharmacy Care Card

The New Life Agency has added a prescription progesterone supplement and RESOLVE: the National Fertility Association to the Fertility Pharmacy Care Card.

RANCHO MIRAGE, Calif. — The New Life Agency has added a prescription progesterone supplement and RESOLVE: the National Fertility Association to the Fertility Pharmacy Care Card.

April 25, 2011
Albertsons reaches out to kids, diabetics

Health and wellness is a major focus for grocer Albertsons, and that also holds true for its youngest of customers. 


Enter Healthy Kidz Club. 


April 13, 2011
FDA accepts regulatory application for Bio-T-Gel

The Food and Drug Administration has accepted a regulatory approval application for a topical treatment for low testosterone made by Teva Pharmaceuticals and BioSante Pharmaceuticals, BioSante said Wednesday.

LINCOLNSHIRE, Ill. — The Food and Drug Administration has accepted a regulatory approval application for a topical treatment for low testosterone made by Teva Pharmaceuticals and BioSante Pharmaceuticals, BioSante said Wednesday.

The two companies said the FDA had accepted their application for Bio-T-Gel and expected to complete its review by mid-November.

April 5, 2011
Bioniche Pharma launches generic Sandostatin

Mylan subsidiary Bioniche Pharma has launched an injectable treatment for a rare metabolic disorder, Mylan said Tuesday.

PITTSBURGH — Mylan subsidiary Bioniche Pharma has launched an injectable treatment for a rare metabolic disorder, Mylan said Tuesday.

Mylan announced the launch of octreotide acetate injection in prefilled syringes, a generic version of Novartis’ Sandostatin, used to treat the disorder acromegaly and suppress or inhibit severe diarrhea related to certain tumors. Acromegaly results from excess growth hormone produced in the pituitary gland, causing fatigue and weakness, body odor and carpal tunnel syndrome.

April 4, 2011
Lilly launches Axiron

A topical medication for treating low testosterone in men now is available, drug maker Eli Lilly said.

INDIANAPOLIS — A topical medication for treating low testosterone in men now is available, drug maker Eli Lilly said.

Lilly announced the availability of Axiron (testosterone), a topical solution designed for application under the arm.

The Food and Drug Administration approved Axiron in November, making it the only testosterone replacement therapy applied to the underarm.

March 31, 2011
Study finds Januvia use could help prevent diabetes

A drug used to treat diabetes also may prevent it, according to a new study published in the journal Experimental Biology and Medicine.

CLEVELAND — A drug used to treat diabetes also may prevent it, according to a new study published in the journal Experimental Biology and Medicine.

Researchers at Case Western Reserve University took specially bred obese, prediabetic rats and gave them either Merck’s Januvia (sitagliptin), placebo or glyburide, an older diabetes drug. Both of the diabetes drugs lowered blood-glucose levels after the rats had eaten, but only Junuvia raised the total output of insulin by the pancreas while lowering levels of glucagon.

March 28, 2011
Study: Counting carbs can improve quality of life in Type 1 diabetes patients on insulin pump therapy

A study published online in the journal Diabetes Care, and slated for the April print issue, suggested that counting carbohydrates could lead to an improvement in quality of life and a reduction in body mass index and waist circumference in patients with Type 1 diabetes who receive continuous subcutaneous insulin infusions.

NEW YORK — A study published online in the journal Diabetes Care, and slated for the April print issue, suggested that counting carbohydrates could lead to an improvement in quality of life and a reduction in body mass index and waist circumference in patients with Type 1 diabetes who receive continuous subcutaneous insulin infusions.

March 24, 2011
Novo Nordisk says Levemir is effective in treating young Type 1 diabetes patients

Novo Nordisk said new data showed that its basal insulin analog is just as effective as human basal insulin in Type 1 diabetes patients ages 2 to 5 years.

COPENHAGEN — Novo Nordisk said new data showed that its basal insulin analog is just as effective as human basal insulin in Type 1 diabetes patients ages 2 to 5 years.

March 14, 2011
Biodel discloses accelerated development plan for diabetes drugs

A drug maker focused on development and commercialization of diabetes treatments unveiled its accelerating clinical development plans of two drug candidates.

DANBURY, Conn. — A drug maker focused on development and commercialization of diabetes treatments unveiled its accelerating clinical development plans of two drug candidates.

Biodel said BIOD-105 and BIOD-107, known as ultra rapid-acting insulins, are designed to result in more rapid insulin action, compared with currently marketed mealtime insulin analogs.

March 11, 2011
GSK, Tolerx's late-stage trial for otelixizumab doesn't meet endpoints

A late-stage trial of a biologic treatment for Type 1 diabetes appears to have failed, according to results announced Friday.

CAMBRIDGE, Mass. — A late-stage trial of a biologic treatment for Type 1 diabetes appears to have failed, according to results announced Friday.

March 4, 2011
Gene mutation, Type 2 diabetes linked in study

A new study revealed that a single gene mutation might be the cause of Type 2 diabetes.

CATANZARO, Italy — A new study revealed that a single gene mutation might be the cause of Type 2 diabetes.

March 4, 2011
Guest Column: Promotion optimization lures shoppers

A funny thing happened on the way to the cash register. A coveted diabetic shopper intent on saving money saw promotions that resonated with value. She was hooked.

On this trip, promotions influenced her to expand her basket from just insulin to related care items, foot cream and a sugar-free treat. It was as if the retailer and suppliers completely understood her daily regimen, lifestyle, shopping behaviors, willingness to spend and purchase triggers. Indeed, they did.

How? They mastered the process of promotion optimization.

March 3, 2011
Endo launches Fortesta

Endo Pharmaceuticals has launched a recently approved testosterone gel for men.

CHADDS FORD, Pa. — Endo Pharmaceuticals has launched a recently approved testosterone gel for men.

Endo announced Thursday the launch of Fortesta, approved by the Food and Drug Administration for treating low testosterone — or low T — in men, which affects about 14 million men in the United States; around 1.3 million of those men currently are receiving treatment, according to Endo.

March 2, 2011
Drug makers file suit against Mylan over generic Vivelle-Dot

A group of drug makers have sued Mylan over its attempt to gain Food and Drug Administration approval for a generic menopause drug, Mylan said Tuesday.

PITTSBURGH — A group of drug makers have sued Mylan over its attempt to gain Food and Drug Administration approval for a generic menopause drug, Mylan said Tuesday.

February 25, 2011
Fatty liver may impose diabetes risk

Over the years, a fatty liver has become an indicator of obesity and insulin resistance among humans, but researchers have found that people with fatty livers are five times more likely to develop Type 2 diabetes than their healthier counterparts.

NEW YORK — Over the years, a fatty liver has become an indicator of obesity and insulin resistance among humans, but researchers have found that people with fatty livers are five times more likely to develop Type 2 diabetes than their healthier counterparts.

February 11, 2011
Makena receives FDA approval

The Food and Drug Administration has approved a drug for preventing preterm births.

SILVER SPRING, Md. — The Food and Drug Administration has approved a drug for preventing preterm births.

The agency announced Friday the approval of Baxter Pharmaceutical Solutions’ Makena (hydroxyprogesterone caproate) injection, for reducing the risk of preterm delivery before 37 weeks of pregnancy in pregnant women with a history of at least one spontaneous preterm birth.

February 3, 2011
Lilly, JDRF enter research agreement

Drug maker Eli Lilly and the Juvenile Diabetes Research Foundation will fund research to find ways to regenerate insulin-producing cells in patients with Type 1 diabetes.

INDIANAPOLIS — Drug maker Eli Lilly and the Juvenile Diabetes Research Foundation will fund research to find ways to regenerate insulin-producing cells in patients with Type 1 diabetes.

The two announced Thursday that ideas included finding ways to grow new insulin-producing cells within a person’s body. Type 1 diabetes, also known as juvenile diabetes, is an autoimmune disease in which the immune system attacks beta cells, the cells that allow the body to produce insulin. As many as 3 million people in the United States have Type 1 diabetes.

January 28, 2011
UT Southwestern may have found potential cure for Type 1 diabetes

Researchers at the University of Texas Southwestern Medical Center suggested that taking away the actions of a certain hormone can alter Type 1 diabetes into "an asymptomatic, noninsulin-dependent disorder."

DALLAS — Researchers at the University of Texas Southwestern Medical Center suggested that taking away the actions of a certain hormone can alter Type 1 diabetes into "an asymptomatic, noninsulin-dependent disorder."

When testing mice, the researchers found that insulin is not depended on when the body's hormone, glucagon, is suppressed.